CN102159548A - 在治疗中有用的酰胺化合物 - Google Patents
在治疗中有用的酰胺化合物 Download PDFInfo
- Publication number
- CN102159548A CN102159548A CN2009801364939A CN200980136493A CN102159548A CN 102159548 A CN102159548 A CN 102159548A CN 2009801364939 A CN2009801364939 A CN 2009801364939A CN 200980136493 A CN200980136493 A CN 200980136493A CN 102159548 A CN102159548 A CN 102159548A
- Authority
- CN
- China
- Prior art keywords
- pyrazole
- carboxamide
- cyanophenyl
- isopropyl
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UDVMXBBSEPROLV-UHFFFAOYSA-N CC(C)C(N(CC1)CC1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O Chemical compound CC(C)C(N(CC1)CC1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O UDVMXBBSEPROLV-UHFFFAOYSA-N 0.000 description 1
- QYDGVWGFJZRANB-UHFFFAOYSA-N CC(C)NC(c1c(C)c(-c(cc2C)ccc2C#N)n[n]1C(C)C)=O Chemical compound CC(C)NC(c1c(C)c(-c(cc2C)ccc2C#N)n[n]1C(C)C)=O QYDGVWGFJZRANB-UHFFFAOYSA-N 0.000 description 1
- LSKWDBADKXIQFN-UHFFFAOYSA-N CC(C)NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O Chemical compound CC(C)NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O LSKWDBADKXIQFN-UHFFFAOYSA-N 0.000 description 1
- SBTLHVUCPBSIBT-UHFFFAOYSA-N CC(C)[n](c(C(NC(C)(C)CO)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC(C)(C)CO)=O)c1C2CC2)nc1-c(cc1)ccc1C#N SBTLHVUCPBSIBT-UHFFFAOYSA-N 0.000 description 1
- XJOSLGZLGUCOCG-UHFFFAOYSA-N CC(C)[n](c(C(NC(C1)C[n]2c1cnc2)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC(C1)C[n]2c1cnc2)=O)c1C2CC2)nc1-c(cc1)ccc1C#N XJOSLGZLGUCOCG-UHFFFAOYSA-N 0.000 description 1
- ZPSGDVZKRMFCMX-UHFFFAOYSA-N CC(C)[n](c(C(NC(CC1)CN(C)C1=O)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC(CC1)CN(C)C1=O)=O)c1C2CC2)nc1-c(cc1)ccc1C#N ZPSGDVZKRMFCMX-UHFFFAOYSA-N 0.000 description 1
- LAZMOKCMPYPKNS-UHFFFAOYSA-N CC(C)[n](c(C(NC1CC1)=O)c1C#N)nc1-c(cc1C)ccc1C#N Chemical compound CC(C)[n](c(C(NC1CC1)=O)c1C#N)nc1-c(cc1C)ccc1C#N LAZMOKCMPYPKNS-UHFFFAOYSA-N 0.000 description 1
- CABXPEWBYIPIMX-UHFFFAOYSA-N CC(C)[n](c(C(NCC(C)(C)O)=O)c1C#N)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NCC(C)(C)O)=O)c1C#N)nc1-c(cc1)ccc1C#N CABXPEWBYIPIMX-UHFFFAOYSA-N 0.000 description 1
- KBORPXVRRGHOJB-UHFFFAOYSA-N CC(C)[n](c(C(NCC(C)=O)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NCC(C)=O)=O)c1C2CC2)nc1-c(cc1)ccc1C#N KBORPXVRRGHOJB-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)[n](c(C(O*)=C)c1C#I)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(O*)=C)c1C#I)nc1-c(cc1)ccc1C#N 0.000 description 1
- FNRNHAYMPUXLIR-UHFFFAOYSA-N CC(C)[n](c(C(OC)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(OC)=O)c1C2CC2)nc1-c(cc1)ccc1C#N FNRNHAYMPUXLIR-UHFFFAOYSA-N 0.000 description 1
- WFWUKTYCNJJESR-UHFFFAOYSA-N CC(C)[n](c(I)c1C)nc1-c(cc1)cc(C)c1C#N Chemical compound CC(C)[n](c(I)c1C)nc1-c(cc1)cc(C)c1C#N WFWUKTYCNJJESR-UHFFFAOYSA-N 0.000 description 1
- MDCSSORWNCMBEV-UHFFFAOYSA-N CC(C)[n](c(I)c1C2CC2)nc1-c(cc1C)ccc1C#N Chemical compound CC(C)[n](c(I)c1C2CC2)nc1-c(cc1C)ccc1C#N MDCSSORWNCMBEV-UHFFFAOYSA-N 0.000 description 1
- FFPYOXYDFNUAFY-UHFFFAOYSA-N CCC(C)[n](c(C(NC)=O)c1CC)nc1-c(cc1)ccc1C#N Chemical compound CCC(C)[n](c(C(NC)=O)c1CC)nc1-c(cc1)ccc1C#N FFPYOXYDFNUAFY-UHFFFAOYSA-N 0.000 description 1
- WZKANHVIGHAWDK-IBGZPJMESA-N CCC(N(CC1)C[C@H]1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O Chemical compound CCC(N(CC1)C[C@H]1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O WZKANHVIGHAWDK-IBGZPJMESA-N 0.000 description 1
- LZIQYEQHLHOHMT-UHFFFAOYSA-N CCNC(c1c(C)c(-c(cc2C)ccc2C#N)n[n]1C(C)C)=O Chemical compound CCNC(c1c(C)c(-c(cc2C)ccc2C#N)n[n]1C(C)C)=O LZIQYEQHLHOHMT-UHFFFAOYSA-N 0.000 description 1
- FKLKEQXJPMTOFB-UHFFFAOYSA-N CCc1c(C(OC)=O)[n](C(C)C)nc1-c(cc1)ccc1C#N Chemical compound CCc1c(C(OC)=O)[n](C(C)C)nc1-c(cc1)ccc1C#N FKLKEQXJPMTOFB-UHFFFAOYSA-N 0.000 description 1
- UEQVWBPSKMYVIQ-UHFFFAOYSA-N CCc1c(N)[n](C(C)C)nc1-c(cc1)ccc1C#N Chemical compound CCc1c(N)[n](C(C)C)nc1-c(cc1)ccc1C#N UEQVWBPSKMYVIQ-UHFFFAOYSA-N 0.000 description 1
- RURICRZQHKXBKR-ZGTOLYCTSA-N C[C@H](CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1COCC1)=O)O Chemical compound C[C@H](CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1COCC1)=O)O RURICRZQHKXBKR-ZGTOLYCTSA-N 0.000 description 1
- UWCYXOGMFRIUGH-UHFFFAOYSA-N Cc1c(C(NC)=O)[n](C2CCC2)nc1-c(cc1)ccc1C#N Chemical compound Cc1c(C(NC)=O)[n](C2CCC2)nc1-c(cc1)ccc1C#N UWCYXOGMFRIUGH-UHFFFAOYSA-N 0.000 description 1
- YOQBZXHUZVMUNY-UHFFFAOYSA-N Cc1c(C(NCC2CC2)=O)[n](C2CCC2)nc1-c(cc1)ccc1C#N Chemical compound Cc1c(C(NCC2CC2)=O)[n](C2CCC2)nc1-c(cc1)ccc1C#N YOQBZXHUZVMUNY-UHFFFAOYSA-N 0.000 description 1
- UHRSJHBPVBVECN-UHFFFAOYSA-N Cc1c(C(OC)=O)[n](C2CC2)nc1-c(cc1)ccc1C#N Chemical compound Cc1c(C(OC)=O)[n](C2CC2)nc1-c(cc1)ccc1C#N UHRSJHBPVBVECN-UHFFFAOYSA-N 0.000 description 1
- TVNPXKQYCRPDND-UHFFFAOYSA-N Cc1c(N)[n](C2CC2)nc1-c(cc1)ccc1C#N Chemical compound Cc1c(N)[n](C2CC2)nc1-c(cc1)ccc1C#N TVNPXKQYCRPDND-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9790208P | 2008-09-18 | 2008-09-18 | |
| US61/097,902 | 2008-09-18 | ||
| PCT/IB2009/054038 WO2010032200A1 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102159548A true CN102159548A (zh) | 2011-08-17 |
Family
ID=41269630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801364939A Pending CN102159548A (zh) | 2008-09-18 | 2009-09-16 | 在治疗中有用的酰胺化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8232269B2 (https=) |
| EP (1) | EP2350017A1 (https=) |
| JP (1) | JP2012502975A (https=) |
| KR (1) | KR20110044304A (https=) |
| CN (1) | CN102159548A (https=) |
| AP (1) | AP2011005611A0 (https=) |
| AU (1) | AU2009294290B2 (https=) |
| BR (1) | BRPI0918935A2 (https=) |
| CA (1) | CA2735931A1 (https=) |
| CL (1) | CL2011000570A1 (https=) |
| CO (1) | CO6351734A2 (https=) |
| DO (1) | DOP2011000083A (https=) |
| EA (1) | EA201100368A1 (https=) |
| EC (1) | ECSP11010901A (https=) |
| IL (1) | IL211479A0 (https=) |
| MA (1) | MA32642B1 (https=) |
| MX (1) | MX2011002899A (https=) |
| PE (1) | PE20110793A1 (https=) |
| WO (1) | WO2010032200A1 (https=) |
| ZA (1) | ZA201102690B (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3，3-二氟环丁烷甲酸的方法 |
| CN112724127A (zh) * | 2019-10-28 | 2021-04-30 | 中国科学院上海药物研究所 | 五元杂环氧代羧酸类化合物及其医药用途 |
| WO2023217203A3 (zh) * | 2022-05-12 | 2024-01-04 | 西北农林科技大学 | 二苯基吡唑类化合物的制备方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2541295T3 (es) * | 2011-04-21 | 2015-07-17 | Orion Corporation | Carboxamidas que modulan el receptor de andrógenos |
| WO2013013190A1 (en) * | 2011-07-21 | 2013-01-24 | The Regents Of The University Of California | Targeting gli proteins in human cancer by small molecules |
| JP6147279B2 (ja) | 2012-02-17 | 2017-06-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | オレキシン−２受容体アンタゴニストの合成において有用な方法および化合物 |
| EP2700635A1 (en) | 2012-08-20 | 2014-02-26 | Basf Se | 5-Trifluoromethylpyrazole amides having herbicidal activity |
| CN110143953B (zh) | 2013-01-23 | 2022-08-26 | 加利福尼亚大学董事会 | 由小分子靶向人癌症中的gli蛋白 |
| CU24275B1 (es) | 2013-02-22 | 2017-10-05 | Pfizer | Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos |
| WO2014143617A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Women's Health, Inc. | Deuterium-enriched tanaproget and processes for its preparation |
| EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| WO2020198583A1 (en) | 2019-03-27 | 2020-10-01 | Insilico Medicine Ip Limited | Bicyclic jak inhibitors and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006111856A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| WO2007043400A1 (ja) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
-
2009
- 2009-09-16 CN CN2009801364939A patent/CN102159548A/zh active Pending
- 2009-09-16 KR KR1020117006161A patent/KR20110044304A/ko not_active Ceased
- 2009-09-16 PE PE2011000628A patent/PE20110793A1/es not_active Application Discontinuation
- 2009-09-16 JP JP2011527444A patent/JP2012502975A/ja not_active Withdrawn
- 2009-09-16 WO PCT/IB2009/054038 patent/WO2010032200A1/en not_active Ceased
- 2009-09-16 CA CA2735931A patent/CA2735931A1/en not_active Abandoned
- 2009-09-16 EP EP09787204A patent/EP2350017A1/en not_active Withdrawn
- 2009-09-16 MX MX2011002899A patent/MX2011002899A/es not_active Application Discontinuation
- 2009-09-16 AP AP2011005611A patent/AP2011005611A0/xx unknown
- 2009-09-16 BR BRPI0918935A patent/BRPI0918935A2/pt not_active IP Right Cessation
- 2009-09-16 EA EA201100368A patent/EA201100368A1/ru unknown
- 2009-09-16 AU AU2009294290A patent/AU2009294290B2/en not_active Expired - Fee Related
- 2009-09-17 US US12/561,398 patent/US8232269B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 IL IL211479A patent/IL211479A0/en unknown
- 2011-03-17 CL CL2011000570A patent/CL2011000570A1/es unknown
- 2011-03-17 EC EC2011010901A patent/ECSP11010901A/es unknown
- 2011-03-17 DO DO2011000083A patent/DOP2011000083A/es unknown
- 2011-03-18 MA MA33710A patent/MA32642B1/fr unknown
- 2011-03-25 CO CO11036952A patent/CO6351734A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02690A patent/ZA201102690B/en unknown
-
2012
- 2012-06-18 US US13/525,893 patent/US20120316150A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006111856A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| WO2007043400A1 (ja) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3，3-二氟环丁烷甲酸的方法 |
| CN112724127A (zh) * | 2019-10-28 | 2021-04-30 | 中国科学院上海药物研究所 | 五元杂环氧代羧酸类化合物及其医药用途 |
| CN112724127B (zh) * | 2019-10-28 | 2023-02-17 | 中国科学院上海药物研究所 | 五元杂环氧代羧酸类化合物及其医药用途 |
| WO2023217203A3 (zh) * | 2022-05-12 | 2024-01-04 | 西北农林科技大学 | 二苯基吡唑类化合物的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MA32642B1 (fr) | 2011-09-01 |
| CO6351734A2 (es) | 2011-12-20 |
| AU2009294290A1 (en) | 2010-03-25 |
| ZA201102690B (en) | 2011-12-28 |
| US20120316150A1 (en) | 2012-12-13 |
| WO2010032200A1 (en) | 2010-03-25 |
| JP2012502975A (ja) | 2012-02-02 |
| PE20110793A1 (es) | 2011-10-31 |
| BRPI0918935A2 (pt) | 2015-12-01 |
| CL2011000570A1 (es) | 2011-06-17 |
| DOP2011000083A (es) | 2011-03-31 |
| CA2735931A1 (en) | 2010-03-25 |
| US20100249091A1 (en) | 2010-09-30 |
| IL211479A0 (en) | 2011-05-31 |
| AU2009294290B2 (en) | 2012-08-30 |
| ECSP11010901A (es) | 2011-04-29 |
| AP2011005611A0 (en) | 2011-04-30 |
| KR20110044304A (ko) | 2011-04-28 |
| US8232269B2 (en) | 2012-07-31 |
| MX2011002899A (es) | 2011-04-11 |
| EP2350017A1 (en) | 2011-08-03 |
| EA201100368A1 (ru) | 2011-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102159548A (zh) | 在治疗中有用的酰胺化合物 | |
| TWI321563B (en) | Compounds useful in therapy | |
| CN104854098B (zh) | 作为ep4拮抗剂的苯并咪唑衍生物 | |
| US20090099209A1 (en) | Compounds Useful in Therapy | |
| US10730856B2 (en) | Benzimidazole derivatives as EP4 ligands | |
| US20080096950A1 (en) | Compounds Useful In Therapy | |
| HK1156028A (en) | Amide compounds useful in therapy | |
| WO2008135824A1 (en) | Oxyalkylpyrazole compounds useful in therapy | |
| HK1124837A (en) | Pyrazole derivatives and their medical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1156028 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110817 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1156028 Country of ref document: HK |